Journal of Leukemia
Open Access
ISSN: 2329-6917
+44 1300 500008
ISSN: 2329-6917
+44 1300 500008
Alvarado Ibarra M
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,
Hematology, Felix Cuevas Y Coyoacan 03100
Mexico
Case Report
Long-Term Outcomes of Tyrosine Kinase Inhibitors Treatment for Chronic Myeloid Leukemia
Author(s): Alvarado Ibarra M, Mena Zepeda V, Alvarez Vera J, Ortiz Zepeda M, Jimenez Alvarado R and Lopez Hernandez MAlvarado Ibarra M, Mena Zepeda V, Alvarez Vera J, Ortiz Zepeda M, Jimenez Alvarado R and Lopez Hernandez M
Introduction: Chronic myeloid leukemia Ph+ (CML) is a myeloproliferative neoplasm that originates in a pluripotent and abnormal bone marrow cell, consistently associated with the BCR-ABL fusion gene, 1 located on the Ph chromosome, represents 15% of all leukemias. Treatment has evolved along with the disease using alkylators, antimetabolites, immunomodulators, and tyrosine kinase inhibitors (TKI), that have significantly improved patient survival, including ponatinib, effective for the T315I mutation.
Objective: To know the overall survival and progression-free survival of TKIs (imatinib, nilotinib and dasatinib) in patients with Ph+ CML treated at the CMN Hematology Service "20 de Noviembre" ISSSTE, in a long-term followup.
Patients and Methods: Over 15 years with Ph+ CML from 1999 to 2016 not treated wi.. View More»
DOI:
10.4172/2329-6917.1000240